You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunologic Suppression

Showing 1 - 25 of 2,400
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Paravertebral Block, Pectoralis and Serratus Plane Nerve Blocks, Breast Cancer Trial (procedure, device, drug)

Not yet recruiting
  • Paravertebral Block
  • +4 more
  • Paravertebral nerve block (PVB)
  • +5 more
  • (no location specified)
Apr 3, 2023

AIDS Trial (Dolutegravir 50 MG plus lamivudine 300 MG; Dolutegravir/lamivudine (50 MG/300 MG))

Not yet recruiting
  • Acquired Immunodeficiency Syndrome
  • Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
  • (no location specified)
Aug 6, 2022

Tuberculosis, HIV-1-infection, Immuno-Deficiency Trial in Worldwide (Intensified TB treatment (initial phase), WHO standard TB

Recruiting
  • Tuberculosis
  • +2 more
  • Intensified TB treatment (initial phase)
  • WHO standard TB treatment (initial phase)
  • Phnom Penh, Cambodia
  • +5 more
May 3, 2022

Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (GSK744, GSK744 LA, TMC278 LA)

Active, not recruiting
Has Results
  • Infection, Human Immunodeficiency Virus
  • HIV Infections
  • Birmingham, Alabama
  • +49 more
Dec 26, 2022

Human Immunodeficiency Virus Type 1 (HIV-1) Trial in Worldwide (Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine -

Active, not recruiting
  • Human Immunodeficiency Virus Type 1 (HIV-1)
  • Cabotegravir - Injectable Suspension (CAB LA)
  • Rilpivirine - Injectable Suspension (RPV LA)
  • Macon, Georgia
  • +29 more
May 31, 2023

HIV, Histoplasmosis Trial in United States (Fluconazole)

Completed
  • HIV Infections
  • Histoplasmosis
  • Birmingham, Alabama
  • +22 more
Oct 26, 2021

Human Immunodeficiency Virus-type 1 Infection Trial in Worldwide (Rilpivirine, Efavirenz, Tenofovir disoproxil fumarate)

Completed
Has Results
  • Human Immunodeficiency Virus-type 1 Infection
  • Douala, Cameroon
  • +17 more
Jan 22, 2021

HIV-1-infection Trial (Fostemsavir 600 MG [Rukobia])

Recruiting
  • HIV-1-infection
  • Fostemsavir 600 MG [Rukobia]
  • Orlando, Florida
    Orlando Immunology Center
Sep 20, 2022

HIV Trial in Denver, Chicago, Cleveland (Ritonavir, Saquinavir, Delavirdine mesylate)

Completed
  • HIV Infections
  • Denver, Colorado
  • +2 more
Oct 27, 2021

HIV (Human Immunodeficiency Virus) Trial in Geita, Kagera (Conditional Cash Transfer)

Recruiting
  • HIV (Human Immunodeficiency Virus)
  • Conditional Cash Transfer
  • Geita, Tanzania
  • +1 more
Aug 10, 2022

Analysis of HIV-1 Replication During Antiretroviral Therapy

Enrolling by invitation
  • HIV
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 13, 2023

    Human Immunodeficiency Virus (HIV) Infection Trial in Maseru, Blantyre (ART first- Therapeutic use trial, TB results first-

    Recruiting
    • Human Immunodeficiency Virus (HIV) Infection
    • ART first- Therapeutic use trial
    • TB results first- Therapeutic use trial
    • Maseru, Lesotho
    • +1 more
    Aug 10, 2022

    Hepatitis B Trial in Worldwide (JNJ-73763989, JNJ-56136379, Entecavir (ETV))

    Active, not recruiting
    • Hepatitis B
    • Baltimore, Maryland
    • +9 more
    Jan 17, 2023

    Following COVID-19 Vaccination in Children, Adolescents, and

    Recruiting
    • COVID-19 Infection
    • +2 more
    • Biospecimen Collection
    • Survey Administration
    • Birmingham, Alabama
    • +54 more
    Jan 30, 2023

    HIV Trial in United States (Indinavir sulfate, Lamivudine, Stavudine)

    Completed
    • HIV Infections
    • Indinavir sulfate
    • +3 more
    • Los Angeles, California
    • +44 more
    Oct 28, 2021

    Leukapheresis Procedures to Obtain Plasma and Lymphocytes for

    Recruiting
    • HIV
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 7, 2023

      Study of Multidrug-Resistant Patient Outcomes With and Without

      Recruiting
      • HIV Infections
      • Multi-Antiviral Resistance
      • No ibalizumab or Pre-ibalizumab treatment
      • On ibalizumab treatment
      • Los Angeles, California
      • +38 more
      Jan 31, 2023

      Skin Diseases Trial in Birmingham (Diphenylcyclopropenone (DPCP))

      Recruiting
      • Skin Diseases
      • Diphenylcyclopropenone (DPCP)
      • Birmingham, Alabama
        Whitaker Clinic
      Apr 14, 2022

      HIV-1-infection Trial in Botswana, Malawi, South Africa (3BNC117-LS-J, 10-1074-LS-J, Placebo for 3BNC117-LS-J)

      Not yet recruiting
      • HIV-1-infection
      • Molepolole, Botswana
      • +8 more
      Sep 8, 2023

      Coronavirus Infection in Primary or Secondary Immunosuppressed

      Unknown status
      • Immune Suppression
      • +4 more
      • Questionnaire
      • Southampton, Hampshire, United Kingdom
        University Hospital Southampton NHS FT
      May 18, 2020

      HIV Trial in United States (Amprenavir, Lamivudine, Zidovudine)

      Completed
      • HIV Infections
      • Birmingham, Alabama
      • +14 more
      Oct 28, 2021

      Upper Aerodigestive Malignancies

      Recruiting
      • Head and Neck Cancer
      • +2 more
      • Collection of biological specimens
      • Baltimore, Maryland
        Johns Hopkins University
      Aug 9, 2023

      HIV Trial in Sevilla (Continue with triple therapy, Switch to DTG + 3TC, Switch to DRV/cobicistat + 3TC)

      Completed
      • HIV Infections
      • Continue with triple therapy
      • +2 more
      • Sevilla, Spain
        Virgen del Rocio University Hospital
      Aug 27, 2021

      Poor Thymic Function, Immunodeficiency, Athymia Trial (biological, procedure, drug)

      Approved for marketing
      • Poor Thymic Function
      • +5 more
      • Cultured Thymus Tissue
      • +2 more
      • (no location specified)
      Mar 23, 2022

      HIV Trial run by the National Cancer Institute (NCI) (Acute Treatment Interruption)

      Recruiting
      • HIV
      • Acute Treatment Interruption
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 11, 2023